

lymphoma and the patient age he has been just followed up for the last 6 months. Blood cell count, serochemical findings including liver enzymes are normal and the liver mass is stable.

Discussion: Primary hepatic lymphoma is defined as lymphoma either confined to the liver or having major liver involvement. It represents less than 1% of all extranodal lymphomas. The exact cause of primary hepatic lymphoma is unknown, and there is no consensus on the best approach for management.

22

Surgery and multiple successive chemotherapy helped to achieve a sustainable remission in patient with advanced MALT lymphoma

E. Shakhnovich^{1*}, A. Kolganov². ¹State Scientific Center of Coloproctology, Department of Chemotherapy, Moscow, Russia, ²Medical Center of Bank of Russia, Department of Haemato-Oncology, Moscow, Russia

Pt suffered from dramatic weight loss and acute pain, however, the CT did not revealed tumour and he was not referred to the oncologist. Only after suffering became unbearable he was admitted to the hospital with advanced lymphoma. Aggressive treatment improved conditions and remission was achieved. Pt E.A, 62 y.o. Diagnosis MALT lymphoma with the involvement of the small intestines and lymph nodes of mesentery with the secretion of the IgA lambda-type paraprotein, IVB stage Immunohistochemistry: proliferation of small lymphocytes with infiltration of intrafollicular structures. Phenotype: CD 20+, CD79+? CD5-, CD10-, CD23-, CD43+/-, Cd11+/- . In 1997 the pt noted the dramatic weight loss (14kg), acute abdominal pain, vomiting. The level of the IgA lambda-type paraprotein was increased (15 g/l). CT did not detect tumour. In December 1999 due to intraperitoneal bleeding he underwent surgery with the resection of the small intestine, sanitisation and drainage of the abdominal cavity. Histological findings helped to set the diagnosis. February 2000 – January 2001 – 7 courses of chemotherapy (Leukeran, Vinblastin, Natulan, Prednisolonum). After that the pt was monitored. In December 2007 the increase of paraprotein (40 g/l) was observed. However the conditions remained stable, and interventions were not conducted. In February 2008 due to intoxication the chemotherapy (Vincristine, Carmustine, Alkeran, Cyclophosphan, Prednisolonum) was started. After 4 courses the pt had serious complications: granulocytopenia (4 grd) and the bilateral mycotic pneumonia. New chemotherapy line (4 courses of Rituximab, Cyclophosphan, Fludara) started in December 2008 reduced intoxication symptoms. August – September 2009 – 2 administration of Rituximab to consolidate the response. From October 2009 – case monitoring. In December 2009 the paraprotein level was 0.9 g/l.

23

A case report of myeloma in gastric MALT lymphoma with bone marrow(BM) involvement: Two distinct entities?

A. Romanelli^{1*}, P. Bernasconi², S. Gambini³, M.G. Alessio⁴, L. Tedeschi¹. ¹San Carlo Borromeo Hospital, Department of Clinical Oncology – Onco-Haematology Unit, Milan, Italy, ²San Carlo Borromeo Hospital, Department of Immunotransfusional Laboratory, Milan, Italy, ³San Carlo Borromeo Hospital, Department of Pathology, Milan, Italy, ⁴San Carlo Borromeo Hospital, Department of Biochemistry Laboratory, Milan, Italy

Plasmocytic differentiation (PD) may be seen in a minority of B-cell non Hodgkin's lymphoma (NHL) but it's frequent in extranodal marginal zone B-cell lymphoma (MALT lymphoma). PD often manifests clinically with secretion on

monoclonal immunoglobulin. In some cases, the distinction between a B-cell NHL with PD and a plasma cell neoplasm on the basis of immunohistochemical analysis on biopsy specimen may be challenging to diagnose. Recent data suggest that flow cytometric immunophenotyping (FCI) of plasma cell might help the differential diagnosis of these two entities. We report a case of MALT gastric lymphoma stage I that, after five years from diagnosis and treatment, showed BM involvement from nodal marginal zone B-cell NHL together gastric relapse, progressive increment of serum monoclonal component IgG-lambda and appearance of free light chain lambda on urine immunofixation. The patient received six cycles of R-CVP achieving a CR on gastric and BM biopsies specimens, but serum monoclonal component level was not affected and on the contrary it increased on. After 10 months BM biopsy detected an infiltration of 40% of small lymphoma cells stained with anti-CD20 monoclonal antibody associated with plasma cell differentiation. Rituximab $\times 4$ were performed, with further increase of serum monoclonal component IgG-lambda (4.9 gr/dl) and persistent BJ proteinuria. A new BM biopsy showed 90% of small lymphoid cell expressing CD20, CD79a, Bcl2 and lambda light chain. FCI of the BM was done and revealed an increased plasma cell population expressing CD38, CD138, CD20, CD56, CD117, but lacked CD 45 and cytoplasmatic light chain lambda. Further appropriate laboratory and radiographic studies defined the diagnosis of low-grade myeloma, small cell type, stage II (D-S) and stage III (ISS) and consistent treatment. FCI of plasma cell in correlation with the clinicopathologic data confirms its usefulness for the identification and characterization of myeloma cell.

Leukaemias

24

Bone marrow necrosis: A challenging condition

I. Faustino^{1*}, L. Viterbo², R. Henrique³, H. Duarte⁴, I. Lucena⁴, J.M. Mariz². ¹Instituto Português de Oncologia do Porto Francisco Gentil, Department of Medical Oncology, Porto, Portugal, ²Instituto Português de Oncologia do Porto Francisco Gentil, Department of Haemato-Oncology, Porto, Portugal, ³Instituto Português de Oncologia do Porto Francisco Gentil, Department of Pathology, Porto, Portugal, ⁴Instituto Português de Oncologia do Porto Francisco Gentil, Department of Nuclear Medicine, Porto, Portugal

Bone marrow necrosis (BMN) is a rare entity, which is generally associated with malignancy. Hematologic malignancies are the underlying cause in almost 60% of the cases, with acute leukemia being the most frequent etiology accounting for 40%. Prognosis is generally poor but in some cases repopulation of the BM cavity with normal hematopoietic cells is seen. Treatment includes supportive measures and treatment of the underlying cause. A 54-year-old man with idiopathic myelofibrosis since 2004, treated with splenectomy and hidroxiurea, was asymptomatic until November/2009, when he presented with asthenia, anorexia and weight loss. Full blood count showed increasing basophiles but bone marrow aspiration didn't reveal leukemic transformation (LT). Two months later, he developed an intense and disabling pain on the lower back leading to hospitalization. Laboratory findings included Hg – 8.7 g/dl, white cell count – $8.07 \times 10^9/L$, platelets – $307 \times 10^3/L$, LDH – 1000 U/L (normal range: 67–190 U/L). During hospitalization, he developed pancytopenia and LDH raised up to 7354 U/L. Bone marrow (BM) aspiration and biopsy showed chronic myelofibrosis with extensive necrosis and no blasts. BM scanning revealed 99m Tc uptake only in proximal third of the left humerus, right humerus's head and both femur's heads. There was also an intense